Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 Shares

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 1,034,482 shares of the firm’s stock in a transaction on Wednesday, March 26th. The stock was bought at an average price of $11.60 per share, with a total value of $11,999,991.20. Following the acquisition, the insider now owns 795,411 shares in the company, valued at $9,226,767.60. This trade represents a -432.71 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Surrozen Stock Performance

Shares of NASDAQ SRZN opened at $11.01 on Friday. Surrozen, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $18.17. The business has a 50 day moving average price of $11.37 and a two-hundred day moving average price of $10.96.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SRZN. HC Wainwright started coverage on shares of Surrozen in a research note on Thursday, January 30th. They issued a “buy” rating and a $32.00 target price for the company. Guggenheim upgraded shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price objective on the stock in a report on Friday, January 3rd.

Institutional Trading of Surrozen

A number of hedge funds have recently made changes to their positions in SRZN. Geode Capital Management LLC raised its holdings in Surrozen by 26.1% in the fourth quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock valued at $321,000 after acquiring an additional 4,630 shares in the last quarter. Trustees of Columbia University in the City of New York bought a new stake in shares of Surrozen in the 4th quarter worth about $688,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Surrozen in the 4th quarter valued at about $928,000. Regents of The University of California bought a new position in shares of Surrozen during the fourth quarter worth about $1,912,000. Finally, Stonepine Capital Management LLC grew its stake in Surrozen by 24.7% in the fourth quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock worth $1,969,000 after purchasing an additional 27,200 shares in the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.